Phase II Trial of Liver Stereotactic Ablative Radiotherapy Added to Standard Immunotherapy and Chemotherapy for Adults with Stage IV Non-Small Cell Lung Cancer

What this Trial Is About

Researchers are evaluating whether adding liver stereotactic ablative radiotherapy L-SABR to the usual drug treatment improves outcomes for people with metastatic non-small cell lung cancer NSCLC. This Phase II trial focuses on patients with stage IV NSCLC who have liver metastases and aims to compare the effectiveness of combined radiation and drug therapy versus drug therapy alone. Participants are randomly assigned to one of two groups. One group receives the standard treatment with anti-PD-L1 based immunotherapy, which may include platinum-based chemotherapy, while also undergoing liver stereotactic ablative radiotherapy L-SABR. L-SABR is delivered during a week when no chemotherapy is given and can be scheduled alongside immunotherapy. The other group receives only the standard immunotherapy and chemotherapy without radiation. During the study, participants will be monitored for progression-free survival over up to four years. Researchers will assess liver function, overall health status using the ECOG Performance Scale, and treatment response. Safety and effectiveness are tracked through regular clinical evaluations and laboratory tests. The study is led by Memorial Sloan Kettering Cancer Center and participation lasts according to treatment and follow-up schedules.

A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)